Scandion Oncology (Sweden) Investor Sentiment

SCOL Stock  SEK 0.06  0  6.02%   
Slightly above 60% of Scandion Oncology's investor base is looking to short. The analysis of current outlook of investing in Scandion Oncology AS suggests that many traders are alarmed regarding Scandion Oncology's prospects. Scandion Oncology's investing sentiment can be driven by a variety of factors including economic data, Scandion Oncology's earnings reports, geopolitical events, and overall market trends.
  
over a year ago at news.google.com         
Colorectal Cancer Treatment Drug Market to Show Immense Growth ... - Bloomberg
Google News at Macroaxis
over a year ago at news.google.com         
Scandion Oncology Announces Positive Data from Part 2 of its ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Invitation to Scandion Oncology webcast and conference call ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Dr Pietrantonio on the CodeBreak 300 Trial in KRAS G12C-mutated ... - OncLive
Google News at Macroaxis
over a year ago at news.google.com         
ColoAlerts Novel mRNA Biomarkers Demonstrate Sensitivity ... - OncLive
Google News at Macroaxis
over a year ago at news.google.com         
Nyhetssvepet mndag 16 oktober - BioStock - Connecting Innovation and Capital
Google News at Macroaxis
over a year ago at news.google.com         
Nyhetssvepet onsdag 13 september - BioStock - Connecting Innovation and Capital
Google News at Macroaxis
over a year ago at news.google.com         
Dr Fakih on the Significance of the PROSPECT Trial in Rectal Cancer - OncLive
Google News at Macroaxis
over a year ago at news.google.com         
Scandion Oncology appoints Lars Damstrup, MD, PhD, as new Chief Medical Officer - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
NexImmune, Inc. Announces John Trainer, Chief Financial Officer to ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Scandion Oncology Interim Report Q2 2023 - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Avelumab Increases PFS Rates in dMMRMSI Metastatic CRC - OncLive
Google News at Macroaxis
over a year ago at news.google.com         
Data from PANTAX trial to be presented at ESMO Congress 2023 - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Invitation to Scandion Oncology webcast and conference call August 23, 2023 - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
The European Patent Office Announces Intention to Grant of Composition-Of-Matter Patent for Scandion...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Scandion Oncology that are available to investors today. That information is available publicly through Scandion media outlets and privately through word of mouth or via Scandion internal channels. However, regardless of the origin, that massive amount of Scandion data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Scandion Oncology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Scandion Oncology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Scandion Oncology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Scandion Oncology alpha.

Scandion Oncology Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Additional Tools for Scandion Stock Analysis

When running Scandion Oncology's price analysis, check to measure Scandion Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scandion Oncology is operating at the current time. Most of Scandion Oncology's value examination focuses on studying past and present price action to predict the probability of Scandion Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scandion Oncology's price. Additionally, you may evaluate how the addition of Scandion Oncology to your portfolios can decrease your overall portfolio volatility.